Domestic pharmaceutical players heaved a sigh of relief in trade on April 3, while the other sectors see intense selling pressure, as the White House has excluded pharmaceuticals products from the ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics ... next-generation antibody drug conjugate (ADC) products for cancer ...

CHF 27 million investment significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with ...

New challenges will also focus on combination therapy, the discovery of other specific targets and the control of the relationship between polymer architecture and conjugate pharmacokinetics at ...

NBE Therapeutics focuses on developing next-generation ADCs, a targeted approach that delivers cancer-fighting agents directly to tumor cells while limiting effects on healthy tissue. ADCs combine the ...

Qfitlia is a small interference RNA therapeutic that utilizes Alnylam Pharmaceutical Inc.'s ALNY ESC-GalNAc conjugate technology. Through the Qfitlia Testing Program with Labcorp, the FDA-cleared ...

Utilising Alnylam Pharmaceuticals’ ESC-GalNAc conjugate technology, Qfitlia prevents bleeds and helps rebalance haemostasis by lowering antithrombin, a protein that inhibits blood clotting. The ...